Lenz Therapeutics Launches ‘Make It VIZZable’ with Sarah Jessica Parker

LENZ Therapeutics (NASDAQ: LENZ) has kicked off 2026 with star power, unveiling the “Make it VIZZable” campaign fronted by actress and style icon Sarah Jessica Parker to promote VIZZ™, the company’s once-daily, prescription eye drop for presbyopia. The multimedia initiative lands just weeks after LENZ inked an exclusive commercialization deal with regional specialist Lunatus to bring VIZZ to over 15 markets across the Middle East, significantly expanding the product’s global footprint. Management says the partnership leverages Lunatus’ ophthalmology sales force and is expected to accelerate international revenue as regulatory filings roll out this quarter. Early momentum appears strong: preliminary Q4 2025 results showed more than 20,000 VIZZ prescriptions filled in the United States, fueling double-digit quarter-over-quarter revenue growth and setting the stage for 2026 guidance to be raised in March. Analysts argue the Parker-led campaign could further widen LENZ’s first-mover advantage in a U.S. presbyopia market of roughly 128 million adults. Investors have noticed: LENZ shares climbed in pre-market trading on the campaign launch, while law firm Pomerantz simultaneously announced it is reviewing the company for potential securities violations—a routine step that often follows sharp stock movements. With celebrity endorsement, fresh international reach and an addressable market that continues to age, LENZ Therapeutics is positioning VIZZ as the clear-eyed choice for readers tired of juggling glasses—placing the company squarely in Wall Street’s line of sight for 2026.